Brain endocannabinoid system is involved in fluoxetine-induced anorexia

References

• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771–784.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585–589.
   PubMed Web of Science ®Google Scholar
• Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151–1154.
   PubMed Web of Science ®Google Scholar
• Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550–557.
   PubMed Web of Science ®Google Scholar
• Kirkham TC. Opioids and feeding reward. Appetite 1991; 17: 74–75.
   PubMed Web of Science ®Google Scholar
• Williams CM, Kirkham TC. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002; 71: 333–340.
   PubMed Web of Science ®Google Scholar
• Chua Jr SC, Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 994–996.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Weatherford SC. Obese and lean Zucker rats differ in preferences for sham-fed corn oil or sucrose. Am J Physiol 1990; 259: R1093 -R1095.
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP, Englemam EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995; 57: 411 —441.
   PubMed Web of Science ®Google Scholar
• Mackay FJ, Dunn NR, Wilton LV, Pierce GL, Freemantle SN, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safe 1997; 6: 235–246.
   PubMed Web of Science ®Google Scholar
• Anelli M, Bizzi A, Caccia S, Codegoni AM, Fracasso C, Garattini S. Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs. J Pharm Pharmacol 1992; 44: 696–698.
   PubMed Web of Science ®Google Scholar
• Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67: 27–55.
   PubMed Web of Science ®Google Scholar
• Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147–156.
   PubMed Web of Science ®Google Scholar
• Moranta D, Esteban S, Garcia-Sevilla JA. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 516–524.
   PubMed Web of Science ®Google Scholar
• Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003;138: 544–553.
   PubMed Web of Science ®Google Scholar
• Prendergast MA, Yells DP, Balogh SE, Paige SR, Hendricks SE. Fluoxetine differentially suppresses sucrose solution consumption in free-fed and food-deprived rats - reversal by amantadine. Med Sci Monit 2002; 8: BR385 -BR390.
   PubMedGoogle Scholar
• Hagan MM, Holguin FD, Cabello CE, Hanscom DR, Moss DE. Combined naloxone and fluoxetine on deprivation-induced binge eating of palatable foods in rats. Pharmacol Biochem Behav 1997; 58: 1103–1107.
   PubMed Web of Science ®Google Scholar
• Churruca I, Casis L, Portillo MP, et al. Fluoxetine alters mu opioid receptor expression in obese Zucker rat hypothalamus. Neurosci Res Commun 2004; 35: 1–7.
   Google Scholar
• Kirkham TC, Williams CM. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 2001; 153: 267–270.
   PubMed Web of Science ®Google Scholar
• Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Down- regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002; 952: 232–238.
   PubMed Web of Science ®Google Scholar
• Simiand J, Keane M, Keane PE, Soubrie P. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9: 179–181.
   PubMed Web of Science ®Google Scholar
• Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 2001; 159: 111–116.
   PubMed Web of Science ®Google Scholar
• Gallate JE, McGregor IS. The motivation for beer in rats: effects of ritanserin, naloxone and SR141716. Psychopharmacology (Berl) 1999; 142: 302–308.
   PubMed Web of Science ®Google Scholar
• Trojniar W, Wise RA. Facilitory effect of delta 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology (Berl) 1991; 103: 172–176.
   PubMed Web of Science ®Google Scholar
• Jarosz PA, Metzger BL. The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating. Biol Res Nurs 2002; 3: 198–209.
   PubMedGoogle Scholar
• Marx J. Drug development. Drugs inspired by a drug. Science 2006; 311: 322–325.
   PubMed Web of Science ®Google Scholar
• Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103–111.
   PubMed Web of Science ®Google Scholar
• Dryden S, Brown M, King P, Williams G. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363–366.
   PubMed Web of Science ®Google Scholar
• Gutiérrez A, Saraclfaar G, Casis L, et al. Effects of fluoxetine administration on neuropeptide Y and orexins in obese Zucker rat hypothalamus. Obes Res 2002; 10: 532–540.
   PubMedGoogle Scholar
• Churruca I, Portillo MP, Gutiérrez A, et al. Effects of fluoxetine administration on regional galanin expression in obese Zucker rat hypothalamus. Nutr Neurosci 2004; 7: 171–175.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Hamilton SH, Masica DN, Beasley CM. Fluoxetine in medically stable, depressed geriatric patients: effect on weight. J Clin Psychopharmacol 1997; 17: 365–369.
   PubMed Web of Science ®Google Scholar
• Oliva JM, Uriguen L, Perez-Rial S, Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 2005; 49: 618–626.
   PubMed Web of Science ®Google Scholar